Showing 5281-5290 of 5644 results for "".
- Nicox Presents First Data on New Class of Nitric Oxide (NO)-Donating Compounds for Glaucoma at ARVOhttps://modernod.com/news/nicox-presents-first-data-on-new-class-of-nitric-oxide-no-donating-compounds-for-glaucoma-at-arvo/2476545/Nicox SA announced that it has presented the first data from a new drug class designed to lower IOP (NO-donating PDE5 inhibitors) at a poster presentation during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The first
- Alcon to Showcase New Clinical Data, Innovative Technology at ASCRShttps://modernod.com/news/alcon-to-showcase-new-clinical-data-innovative-technology-at-ascrs/2476542/Alcon will feature new clinical data along with innovative product designs and technology for the Cataract Refractive Suite during the American Society of Cataract and Refractive Surgery (ASCRS) 2019 annual meeting, taking place May 3-7 in San Diego. The company, which recently became an independ
- New Mobile Platform Records Patient Outcomes After Cataract Surgeryhttps://modernod.com/news/new-mobile-platform-records-patient-outcomes-after-cataract-surgery/2476543/Rayner has developed RayPRO, a mobile phone and web-based app for collecting patient-reported outcomes (PROs) for 3 years after surgery. The company says this is the first time such software has been available for free to ophthalmic surgeons. It is a bespoke platform that has been specific
- Allergan CEO Saunders Wins Vote to Keep Chairman Rolehttps://modernod.com/news/allergan-ceo-saunders-wins-vote-to-keep-chairman-role/2476540/Allergan shareholders have voted down a nonbinding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders, as
- Atia Vision Closes $20M In Series D Financing to Fund Accommodating IOLhttps://modernod.com/news/atia-vision-closes-20m-in-series-d-financing-to-fund-accommodating-iol/2476533/Atia Vision, a Shifamed portfolio company developing a modular presbyopia-correcting accommodating IOL, announced initial closing of its committed $20 million Series D preferred stock
- New World Medical Recognizes the Recipients of its 2019 Humanitarian Project Award, Health Outcomes Research Award and Fellowship Awardshttps://modernod.com/news/new-world-medical-recognizes-the-recipients-of-its-2019-humanitarian-project-award-health-outcomes-research-award-and-fellowship-awards/2476528/New World Medical has announced the recipients of its annual Humanitarian Project Award, Health Outcomes Research Award, and Fellowship Awards. The Humanitarian Project Award supports a non-profit or academic institution that provides ophthalmic care and skills-transfer. The Health Outcomes Resea
- EyePoint Pharmaceuticals Presents Positive Yutiq 36-Month Follow-Up Phase 3 Data at ARVOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutiq-36-month-follow-up-phase-3-data-at-2019-arvo-annual-meeting/2476523/EyePoint Pharmaceuticals announced the presentation of 36-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18-mg micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The data
- Verseon Presents Oral Drug Candidate for Diabetic Eye Diseasehttps://modernod.com/news/verseon-presents-oral-drug-candidate-for-diabetic-eye-disease/2476516/Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s ARVO 2019 annual meeting in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injecti
- Sight Sciences Announces Launches of TearCare and the Enhanced OMNI Systemhttps://modernod.com/news/sight-sciences-announces-official-launches-of-tearcare-and-the-enhanced-next-generation-omni-system/2476517/Sight Sciences announced the official commercial launch of TearCare and the introduction of an aesthetically and ergonomically enhanced OMNI Surgical System, which was initially launched in February 2018. The rollout of the new devices will include product dem
- ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Studyhttps://modernod.com/news/reneuron-announces-presentation-of-updated-efficacy-and-safety-data-from-retinitis-pigmentosa-study/2476502/ReNeuron Group announced updated positive preliminary results in the company’s ongoing phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2a part of the trial have demonstr